(HEPA) – Company Press Releases
-
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
-
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
-
Hepion Pharmaceuticals to Present at NASH-TAG 2024
-
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
-
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
-
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
-
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
-
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
-
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
-
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
-
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
-
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
-
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
-
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
-
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
-
Hepion Pharmaceuticals Announces Management Changes
-
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
-
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
-
Theralase(R) Announces Appointment of New Independent Director
-
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
-
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
-
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
-
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
-
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
-
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
-
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
-
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
-
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
-
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
-
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies
-
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
-
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
-
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023
-
Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements
-
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
-
Hepion Pharmaceuticals to Present Rencofilstat’s Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit
-
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
-
Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
-
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
-
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
-
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
-
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
-
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
-
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
-
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
-
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders
-
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
-
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
-
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
Back to HEPA Stock Lookup
